“We are already in a situation where we do not have vaccines, and it would be extremely unfortunate for countries to impose a travel requirement on vaccination certificates, while the rest of the world has not had the chance to access vaccines.”
Vaccine passports are documents showing that travelers have been vaccinated against COVID-19 or recently tested negative for the virus. Technology companies and travel-related trading groups in some affluent countries are developing and testing passports to encourage travel.
The issue of vaccine passports has been a much debated topic all over the world, including in the United States and Israel. One question concerns whether governments, employers, and organizers of large gatherings have a right to know about a person’s viral status. Many disagree on what the right balance is between a person’s right to medical privacy and the collective right of groups of people not to be infected with a dangerous disease.
Critics also point out that such vaccine passes allow discrimination against poor nations that do not have clear access to vaccines.
Only 2% of all vaccine doses administered globally have been in Africa, according to the World Health Organization.
The Africa CDC warned last week that the continent is unlikely to reach its vaccination targets amid delivery delays from a major producer. Africa has largely relied on the global COVAX initiative, which aims to ensure that low- and middle-income countries have fair access to the shoots. But the Serum Institute of India recently announced that as many as 90 million doses of the AstraZeneca vaccine destined for COVAX worldwide will be delayed until the end of ril as the Indian government laughs at an increase in infections at home.
Amid delays in COVAX shipments, the African Union Vaccine Acquisition Trust last week signed an agreement with Johnson & Johnson for 220 million doses of its vaccine to be delivered before the third quarter of this year with the option to acquire another 180 million doses by 2022.
Africa’s goal is to vaccinate 60% of its 1.3 billion people by the end of 2022. This goal may not be achieved without the widespread use of the AstraZeneca vaccine, which is widely seen as the key to the global strategy to eradicate the coronavirus pandemic. The vaccine from the Anglo-Swedish drug manufacturer is cheerful and easier to store than many others.
Africa has confirmed more than 4.3 million cases, including 114,000 deaths, representing about 3.3% of the global case load. However, some experts are concerned that the continent will suffer greatly in the long run if more of its people are not vaccinated in the pursuit of so-called herd immunity, when enough people are protected through infection or vaccination to make it difficult for a virus to continue. to spread. That means about 1.5 billion vaccine doses for Africa or less if the Johnson & Johnson vaccine with one dose is very widespread.
“In terms of trade and travel, the world will look at which nations are gaining herd immunity and are safe,” wrote Ugandan health contractor Dr. Ian Clarke in a recent column in the local Sunday Vision news person. “If Uganda remains like a pocket on COVID-19, while other countries have developed herd immunity, we can expect travel consultants from embassies that it is not safe to visit Uganda.”
In a sign of what could come next, Kenya reacted angrily to the British government’s decision to ban most travelers from the East African country because a significant number of them test positive for a variant first found in South Africa. UK travel restrictions begin Friday.
Kenya has retaliated by making it mandatory for all passengers departing from or transiting through UK airports to undergo a 14-day quarantine at a government facility at their own expense. Authorities also accused in a statement that the British government’s decision “appears to be motivated by a discriminatory policy against certain countries and peoples.”